Collaboration Opportunities

Dr. Michael Freeley led a collaborative project with an international life sciences company where he performed the first RNAi library screens in primary human T-cells using their proprietary self-delivering RNAi technology (Freeley et al. 2015, J. Biomolecular Screening). He has also carried out contract research for a pharmaceutical company to screen small molecule drugs to evaluate their anti-inflammatory potential in in-vitro T-cell assays